1
|
Asada‐Mikami R, Heike Y, Kanai S, Azuma M, Shirakawa K, Takaue Y, Krasnykh V, Curiel DT, Terada M, Abe T, Wakasugi H. Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells. Jpn J Cancer Res 2001; 92:321-7. [PMID: 11267943 PMCID: PMC5926705 DOI: 10.1111/j.1349-7006.2001.tb01098.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Dendritic cells (DC) are important antigen-presenting cells in the development of an anti-tumor T cell response. To extend the range of current immuno / gene therapies, we tested luciferase-expressing RGD-adenovirus (Ad) (Ad5lucRGD)-mediated transduction into DC. Phenotypically characterized DC were generated from peripheral blood CD14(+) cells by incubation with granulocyte-macrophage colony-stimulating factor, interleukin-4 and tumor necrosis factor alpha. On the 7th day of culture, the cells became mature DC with a CD1a(+), CD11c(+), CD80(+), CD83(+), CD86(+), human leukocyte antigen (HLA)-DR(+), CD14- phenotype. The expression of alpha( v)beta(3) integrin was enhanced on day 3 and returned to the basal level on day 7. We then compared the transduction efficiency of an Ad5lucRGD system to that using conventional Ad, in cells harvested on days 1, 3 and 7 of culture. Luciferase activity was negligible in AdCMVLuc, but remarkable in cells processed with Ad5lucRGD. Activity was maximal in cells that had been cultured for 3 days. Recombinant Ad5 fiber knob protein blocked AdCMVLuc- and Ad5lucRGD-mediated gene transduction by 90% and 20%, respectively. Surface markers and cytokine production were not affected by Ad5lucRGD-mediated transduction.
Collapse
Affiliation(s)
- Rumiko Asada‐Mikami
- Pharmacology Division, National Cancer Center Research Institute, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
- Department of Hygiene, Kyoto Prefectural University of Medicine, 465 Kajii‐cho, Kawaramachi‐Hirokoji, Kamigyo‐ku, Kyoto 602‐8566
| | - Yuji Heike
- Department of Medical Oncology and Clinical Research National Shikoku Cancer Center, 13 Horino‐uchi, Matsuyama, 790‐0007
| | - Sachiyo Kanai
- Pharmacology Division, National Cancer Center Research Institute, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
| | - Masato Azuma
- Pharmacology Division, National Cancer Center Research Institute, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
| | - Kazuo Shirakawa
- Pharmacology Division, National Cancer Center Research Institute, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
| | - Yoichi Takaue
- Department of Medical Oncology, Hematopoietic Stem Cell Transplant/Immuno Therapy Division, National Cancer Center Hospital, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
| | - Victor Krasnykh
- Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - David T. Curiel
- Gene Therapy Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Masaaki Terada
- Genetic Division, National Cancer Center Research Institute, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
| | - Tatsuo Abe
- Department of Hygiene, Kyoto Prefectural University of Medicine, 465 Kajii‐cho, Kawaramachi‐Hirokoji, Kamigyo‐ku, Kyoto 602‐8566
| | - Hiro Wakasugi
- Pharmacology Division, National Cancer Center Research Institute, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045
| |
Collapse
|
2
|
Kerrebijn JD, Balm AJ, Freeman JL, Dosch HM, Drexhage HA. Who is in control of the immune system in head and neck cancer? Crit Rev Oncol Hematol 1999; 31:31-53. [PMID: 10532189 DOI: 10.1016/s1040-8428(99)00011-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Affiliation(s)
- J D Kerrebijn
- Department of Otolaryngology/Head and Neck Surgery, Mount Sinai Hospital, Toronto, Ont., Canada
| | | | | | | | | |
Collapse
|